Recurrent Pregnancy Loss in Indore: Causes, Diagnostics & Evidence-Based Treatment

Recurrent Pregnancy Loss is defined by the loss of two or more clinically recognised pregnancies before fetal viability, typically set at 20–24 weeks of gestation. The distinction between RPL and sporadic miscarriage is clinically important: sporadic losses are common and often random chromosomal events, while RPL points to an underlying, often correctable cause that deserves systematic investigation.

In Indore, many couples first encounter RPL after a second loss and are told to 'try again naturally.' This wait-and-see approach, while sometimes appropriate after a single loss, is not the standard of care for RPL. Current international guidelines — including those from the European Society of Human Reproduction and Embryology (ESHRE) — recommend initiating investigations after two consecutive losses, particularly in women over 35.

Understanding RPL also means distinguishing it from infertility. Many RPL couples conceive without difficulty; their challenge is sustaining the pregnancy. This distinction shapes the entire diagnostic and treatment pathway. The HomeIVF Medical Board follows evidence-based protocols to identify whether your losses share a common biological thread — and to act on it decisively.

The causes of recurrent pregnancy loss span genetics, anatomy, immunology, endocrinology, and thrombophilia — and in a significant minority of couples, no single cause is identified even after full workup (unexplained RPL).

Genetic factors are the most frequent culprit. Random embryonic aneuploidy explains most early losses, but parental chromosomal structural variants — such as balanced translocations — are found in 3–5% of RPL couples and substantially increase miscarriage risk with each pregnancy.

Uterine structural anomalies, including a septate uterus, submucosal fibroids, and intrauterine adhesions (Asherman's syndrome), are identified in 10–15% of RPL cases. These conditions are particularly relevant for women in Indore who may have had prior uterine surgeries or D&C procedures.

Antiphospholipid Syndrome (APS) — an autoimmune disorder causing abnormal clotting — is one of the most important treatable causes, found in 10–15% of RPL patients. Endocrine factors including polycystic ovary syndrome (PCOS), poorly controlled diabetes, and thyroid dysfunction (both hypo- and hyperthyroidism) are especially prevalent in the Madhya Pradesh population and must be screened systematically.

Thrombophilias such as Factor V Leiden mutation and MTHFR variants are debated but remain part of many Indian RPL panels, given the clinical overlap with APS-like presentations seen locally.

RPL does not always announce itself dramatically. Many losses occur in the first trimester before significant symptoms develop, making it easy for couples — and sometimes clinicians — to minimise the pattern. Recognising the signs that warrant urgent evaluation can save months of unnecessary delay.

Recurrent vaginal bleeding or spotting in early pregnancy, particularly between weeks 5 and 10, combined with falling or stagnant hCG levels, is a key early indicator. Cramping that mirrors menstrual pain in the first trimester, especially when accompanied by the passage of tissue, should prompt immediate ultrasound evaluation.

Beyond the physical, the psychological burden of RPL is significant and clinically recognised. Anxiety, hypervigilance in subsequent pregnancies, and depression are common sequelae that affect treatment adherence. Couples in areas like Sudama Nagar or Rau in Indore who lack local access to RPL specialists often delay care precisely because each appointment requires significant travel and time off work — compounding emotional distress.

If you have experienced two or more pregnancy losses, regardless of whether each loss was 'explained' at the time, this is the threshold at which a structured RPL workup with the HomeIVF Medical Board is clinically warranted and recommended.

A gold-standard RPL workup in Indore covers five domains: genetic testing, uterine assessment, thrombophilia and immunological screening, endocrine profiling, and lifestyle factors. Skipping any domain risks missing a treatable cause.

Genetic investigations include parental karyotyping (peripheral blood chromosomal analysis) for both partners. Where products of conception (POC) are available from a recent loss, chromosomal microarray or karyotyping of fetal tissue is strongly advised — it provides the most actionable data about why that specific pregnancy was lost.

Uterine assessment is best achieved with a combination of transvaginal ultrasound (TVS), saline infusion sonohysterography (SIS), and in selected cases, diagnostic hysteroscopy. These procedures can identify polyps, fibroids, septa, and adhesions with high accuracy.

Blood investigations should include antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta2 glycoprotein), thyroid function (TSH, Free T4), fasting glucose, HbA1c, and prolactin. Inherited thrombophilia panels covering Factor V Leiden, Prothrombin G20210A, and MTHFR C677T are offered based on clinical history.

HomeIVF coordinates all these investigations with accredited partner laboratories in Indore, ensuring samples are collected at home where possible and results are reviewed by the HomeIVF Medical Board within a structured timeline — typically completing the core panel within two weeks.

Treatment of RPL is cause-specific, and an accurate diagnosis is the most important determinant of outcome. Generic progesterone supplementation for every RPL patient — a common practice in many Indore clinics — is not supported by current evidence for all causes and may delay identification of the real problem.

For APS, the combination of low-dose aspirin and low molecular weight heparin (LMWH) from early pregnancy has the strongest evidence base, with live-birth rates improving from approximately 10% (untreated) to 70–80% with treatment. HomeIVF senior specialists manage this protocol through home monitoring of coagulation parameters.

For uterine causes, surgical correction — hysteroscopic septum resection, polypectomy, or myomectomy — performed before the next conception attempt significantly reduces recurrence risk. The HomeIVF Medical Board coordinates surgical referrals with trusted Indore-based operating theatres and provides post-operative monitoring.

For endocrine causes, optimising thyroid function (targeting TSH below 2.5 mIU/L in the preconception period), managing PCOS with evidence-based protocols, and correcting hyperprolactinaemia all demonstrably reduce miscarriage recurrence rates.

For chromosomal causes in parents with balanced translocations, or for unexplained RPL with multiple failed pregnancies, Preimplantation Genetic Testing for Aneuploidy (PGT-A) combined with IVF is discussed. HomeIVF IVF packages start from ₹1.5 lakh and include consultation, monitoring, and cycle management reviewed by the HomeIVF Medical Board.

One of the most significant barriers to RPL management in Indore is the logistics of care. Couples living in Vijay Nagar, Palasia, or further-out localities like Rau face a difficult reality: repeat blood draws, follicle tracking scans, and medication titrations typically require multiple clinic visits per week during a treatment cycle. For working professionals or those with children at home, this is often unsustainable.

HomeIVF's model changes this. Trained fertility nurses visit patients at their Indore homes for blood collections, ultrasound coordination, and medication administration guidance. All clinical data is transmitted in real time to the HomeIVF Medical Board, which reviews results and adjusts protocols with the same rigour as an in-clinic consultation — without the waiting room.

For RPL patients specifically, home monitoring during early pregnancy is transformative. Serial beta-hCG measurements, early viability scans, and progesterone checks can be conducted on schedule without the anxiety of a hospital commute. Early identification of a failing pregnancy allows for faster clinical response, including timely initiation of supportive medications where indicated.

This model also ensures continuity: the same medical team reviews every data point across your entire treatment journey, building a longitudinal clinical picture that isolated clinic visits cannot replicate. For RPL in Indore, continuity of care is not a luxury — it is clinically essential.

Couples in Indore understandably want to know: what are our chances, and how long will this take? Honest answers to these questions are a hallmark of the HomeIVF approach.

Success rates depend heavily on the identified cause. Couples with APS treated with aspirin and heparin can expect live-birth rates of 70–80% in subsequent pregnancies. Those with corrected uterine anomalies see miscarriage recurrence rates fall by approximately 50%. Couples with unexplained RPL have a naturally favourable prognosis — approximately 60–70% live-birth rate in the next pregnancy even without specific treatment — but benefit from close monitoring and emotional support.

For couples pursuing IVF with PGT-A, IVF success rates in India typically range from 40–55% per cycle depending on age and cause, with PGT-A substantially reducing the risk of transferring aneuploid embryos.

Timeline-wise, the initial workup takes two to four weeks. Cause-specific treatment initiation follows within one menstrual cycle in most cases. Surgical corrections, where needed, are typically scheduled within six to eight weeks. The HomeIVF Medical Board sets clear milestones so you always know where you are in your care plan — reducing uncertainty, which is itself a major stressor for RPL couples in Indore and across India.

Indore is Madhya Pradesh's largest city, with a rapidly expanding healthcare ecosystem — yet RPL-specific, protocol-driven care remains inconsistently available. Couples in areas like Sudama Nagar or the outskirts near Rau often report being referred between generalists and obstetricians without ever reaching a reproductive medicine specialist with a structured RPL protocol.

Language and cultural barriers matter too. Discussions about recurrent pregnancy loss carry significant emotional and sometimes social weight in Indian families. The HomeIVF platform offers consultations in Hindi and English, with care coordinators who understand the specific sensitivities around pregnancy loss in the Indore context — including family pressure, religious considerations around certain treatments, and privacy concerns.

Cost transparency is another barrier. Many couples in Indore have encountered hidden investigation costs or unclear treatment pricing. HomeIVF provides itemised care plans before any investigation begins, so families can make informed decisions without financial surprises.

Finally, the shortage of post-loss psychological support in Indore is real. HomeIVF integrates mental health check-ins within the RPL care pathway — not as an add-on, but as a recognised clinical component. Grief counselling, anxiety management strategies, and peer connection resources are offered to every RPL couple, recognising that emotional recovery and clinical recovery must happen together.